MYX 4.50% $4.03 mayne pharma group limited

$1 Here we come, page-53

  1. 6,194 Posts.
    lightbulb Created with Sketch. 2923
    Thanks Mick.., I like empirical rather than anecdotal assessment...+

    So undervalued, yet our half year numbers last month is the rosiest in the last 2 years. In three years, revenue has actually grown at a 27% annual rate. Fundamental value style funds should be lining up like ants to a sugar bowl for MYX on valuation alone...

    As far as I can see, the more recent SP death spiral is based on market sentiment (hard to quantify and prove unfortunately) thus far and on previous technical trend price action. Nothing fundamentally, structurally and even cyclically in the outlook to drive SP this far down.

    We've been pumping new products into the market and a little hiccup on generics sales last half. Which board reports will hardly a dent on the 2019 $A561.43m projected revenue...

    Am I missing anything?
    Last edited by Exised: 19/03/19
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.